Home・Elenco Azioni・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Aperta

SettoreSettore sanitario

2.34 -4.88

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.41

Massimo

2.5

Metriche Chiave
By Trading Economics
Entrata	14M -1M
Vendite	16M 21M
EPS	-0.003
Margine di Profitto	-4.943
Dipendenti	81
EBITDA	15M 657K

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+102.01% upside

Dividendi
By Acuity
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	324M 1B
Apertura precedente	7.22
Chiusura precedente	2.34

Notizie sul Sentiment di mercato

By Acuity

34%

66%

130 / 340 Classifica in Healthcare

Lexicon Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 ago 2026, 19:56 UTC

Lexicon Pharmaceuticals shares are higher today, reflecting strong momentum amid easing inflation concerns from declining crude oil prices. No specific news was identified.

31 lug 2026, 19:46 UTC

Lexicon Pharmaceuticals Inc shares are lower today, reflecting broader market trends amid rising yields and crude oil prices contributing to inflation concerns.

30 lug 2026, 23:11 UTC

Lexicon Pharmaceuticals Inc shares are lower in after-market hours. The decline follows broader market uncertainty after the Federal Reserve's interest rate decision.

29 lug 2026, 21:02 UTC

Lexicon Pharmaceuticals Inc shares are lower in after-market trading, reflecting broader market declines amid rising oil prices and geopolitical tensions in the Middle East.

27 lug 2026, 19:03 UTC

Lexicon Pharmaceuticals Inc is trading lower today, breaking a trend of higher daily closes. Broader market declines and falling oil prices may influence sentiment.

24 lug 2026, 20:07 UTC

Lexicon Pharmaceuticals Inc shares are lower today, reversing from earlier gains amid broader market volatility influenced by falling oil prices and inflation concerns.

22 lug 2026, 19:02 UTC

Lexicon Pharmaceuticals Inc shares are lower today, continuing a decline since Tuesday's close. The stock remains below its 20-day moving average.

21 lug 2026, 19:42 UTC

Lexicon Pharmaceuticals is higher as the market gains momentum, driven by strong performances from major companies and a resurgence in semiconductor stocks.

20 lug 2026, 19:06 UTC

Lexicon Pharmaceuticals Inc shares are lower today, following three days of gains. Broader market declines are linked to rising US Treasury yields and oil prices above $90.

Confronto tra pari

Modifica del prezzo

Lexicon Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

102.01% in crescita

Previsioni per 12 mesi

Media 5.03 USD 102.01%

Alto 6 USD

Basso 3.1 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lexicon Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 3 che hanno fornito valutazioni azionarie a Lexicon Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

130 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.